Manufacturers of opioid overdose reversal drugs, including several generics firms, intend produce an additional 25m doses of their products in the US following a meeting with the White House Office of National Drug Control Policy.
Hosted by ONDCP director Rahul Gupta and White House Domestic Policy Council advisor Neera Tanden, the meeting on 4 June focused on increasine availability of overdose reversal
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?